PMC:6640909 / 7350-10342 JSONTXT

{"project":"TEST0","denotations":[{"id":"31100109-228-233-7123","span":{"begin":1169,"end":1170},"obj":"[\"26922275\"]"},{"id":"31100109-11-17-7124","span":{"begin":1175,"end":1177},"obj":"[\"16219658\"]"},{"id":"31100109-237-243-7125","span":{"begin":1383,"end":1385},"obj":"[\"28781010\"]"},{"id":"31100109-9-15-7126","span":{"begin":1387,"end":1389},"obj":"[\"21515076\"]"},{"id":"31100109-236-242-7127","span":{"begin":1496,"end":1498},"obj":"[\"28781010\"]"},{"id":"31100109-9-15-7128","span":{"begin":1500,"end":1502},"obj":"[\"21515076\"]"},{"id":"31100109-227-233-7129","span":{"begin":1628,"end":1630},"obj":"[\"16219658\"]"},{"id":"31100109-12-18-7130","span":{"begin":1635,"end":1637},"obj":"[\"16198246\"]"},{"id":"31100109-235-241-7131","span":{"begin":1712,"end":1714},"obj":"[\"28371075\"]"},{"id":"31100109-223-229-7132","span":{"begin":1829,"end":1831},"obj":"[\"19497443\"]"},{"id":"31100109-222-228-7133","span":{"begin":1958,"end":1960},"obj":"[\"27623098\"]"},{"id":"31100109-9-15-7134","span":{"begin":1962,"end":1964},"obj":"[\"19752370\"]"},{"id":"31100109-236-242-7135","span":{"begin":2254,"end":2256},"obj":"[\"22458997\"]"},{"id":"31100109-234-240-7136","span":{"begin":2367,"end":2369},"obj":"[\"25581033\"]"},{"id":"31100109-9-15-7137","span":{"begin":2371,"end":2373},"obj":"[\"21986099\"]"},{"id":"31100109-234-240-7138","span":{"begin":2508,"end":2510},"obj":"[\"22438521\"]"},{"id":"31100109-232-238-7139","span":{"begin":2648,"end":2650},"obj":"[\"25612862\"]"},{"id":"31100109-12-18-7140","span":{"begin":2655,"end":2657},"obj":"[\"24931289\"]"},{"id":"31100109-214-220-7141","span":{"begin":2746,"end":2748},"obj":"[\"25612862\"]"},{"id":"31100109-12-18-7142","span":{"begin":2753,"end":2755},"obj":"[\"24931289\"]"},{"id":"31100109-109-115-7143","span":{"begin":2989,"end":2991},"obj":"[\"28198133\"]"}],"text":"Recommendation Class Level References\nIt is recommended that reversible causes of heart failure are ruled out. I B\nLT-MCS implantation should be considered in patients with the following: New York Heart Association functional class IIIB–IV and\nEjection fraction ≤25% and\nAt least one of the following criteria:     ○ INTERMACS 2–4\n    ○ Inotrope dependence\n    ○ Progressive end-organ dysfunction\n    ○ Peak VO2 \u003c12 ml/kg/min\n    ○ Temporary MCS dependence IIa B\nLT-MCS implantation may be considered in patients with: New York Heart Association functional class IIIB–IV and\nEjection fraction ≤25% and\n    ○ To reverse elevated pulmonary vascular resistance or potentially reversible renal failure in potential heart transplant candidates\n    ○ To allow time for transplant contraindications to be reversed such as recent cancer, obesity and recovering drug and alcohol dependence in potential heart transplant candidates IIb B\nPatient characteristics associated with a high risk of poor outcome post-left ventricular assist device\nLT-MCS in patients with advanced age, after careful evaluation of comorbidities and frailty, should be considered. IIa C [3, 22–25]\nLT-MCS in patients with peripheral vascular disease, depending on its severity, may be considered. IIb C\nLT-MCS in patients with active systemic bacterial/fungal infection is not recommended. III B [26, 27]\nIn patients with well controlled HIV, hepatitis B or hepatitis C, LT-MCS should be considered. IIa B [26, 27]\nIn patients with diabetes with poor glycaemic control or end-organ complications, LT-MCS may still be considered. IIb B [22, 28–30]\nLT-MCS may be considered in patients with chronic dialysis. IIb C [31–34]\nLT-MCS implantation in patients with haemostatic deficiencies and coagulopathies may be considered. IIb B [35–38]\nLT-MCS implantation in patients with untreated aortic regurgitation or mechanical aortic valve is not recommended. III C [39, 40]\nLT-MCS in patients with untreated severe mitral stenosis is not recommended. III C\nLT-MCS implantation in patients with irreversible liver dysfunction, as diagnosed by liver enzyme laboratory tests and the Model of End-stage Liver Disease score, is generally not recommended. III B [41]\nIn patients with poor neurological and cognitive function, LT-MCS implantation is not recommended. III B [42, 43]\nFrail patients and patients with limited mobility may, after careful evaluation, be considered for LT-MCS implantation. IIb B [44–48]\nLT-MCS in patients who are living alone or who are suffering from depression should, after careful evaluation, be considered. IIa C [19, 49–53]\nLT-MCS implantation in patients who suffer from dementia is not recommended. III C [19, 49–53]\nLT-MCS implantation in patients with active substance abuse, not willing to cease the abuse, is not recommended. III C\nLT-MCS implantation in patients with malignancies may be considered if expected survival is \u003e1 year. IIb C [33]"}

{"project":"MyTest","denotations":[{"id":"31100109-26922275-28905183","span":{"begin":1169,"end":1170},"obj":"26922275"},{"id":"31100109-16219658-28905184","span":{"begin":1175,"end":1177},"obj":"16219658"},{"id":"31100109-28781010-28905185","span":{"begin":1383,"end":1385},"obj":"28781010"},{"id":"31100109-21515076-28905186","span":{"begin":1387,"end":1389},"obj":"21515076"},{"id":"31100109-28781010-28905187","span":{"begin":1496,"end":1498},"obj":"28781010"},{"id":"31100109-21515076-28905188","span":{"begin":1500,"end":1502},"obj":"21515076"},{"id":"31100109-16219658-28905189","span":{"begin":1628,"end":1630},"obj":"16219658"},{"id":"31100109-16198246-28905190","span":{"begin":1635,"end":1637},"obj":"16198246"},{"id":"31100109-28371075-28905191","span":{"begin":1712,"end":1714},"obj":"28371075"},{"id":"31100109-19497443-28905192","span":{"begin":1829,"end":1831},"obj":"19497443"},{"id":"31100109-27623098-28905193","span":{"begin":1958,"end":1960},"obj":"27623098"},{"id":"31100109-19752370-28905194","span":{"begin":1962,"end":1964},"obj":"19752370"},{"id":"31100109-22458997-28905195","span":{"begin":2254,"end":2256},"obj":"22458997"},{"id":"31100109-25581033-28905196","span":{"begin":2367,"end":2369},"obj":"25581033"},{"id":"31100109-21986099-28905197","span":{"begin":2371,"end":2373},"obj":"21986099"},{"id":"31100109-22438521-28905198","span":{"begin":2508,"end":2510},"obj":"22438521"},{"id":"31100109-25612862-28905199","span":{"begin":2648,"end":2650},"obj":"25612862"},{"id":"31100109-24931289-28905200","span":{"begin":2655,"end":2657},"obj":"24931289"},{"id":"31100109-25612862-28905201","span":{"begin":2746,"end":2748},"obj":"25612862"},{"id":"31100109-24931289-28905202","span":{"begin":2753,"end":2755},"obj":"24931289"},{"id":"31100109-28198133-28905203","span":{"begin":2989,"end":2991},"obj":"28198133"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Recommendation Class Level References\nIt is recommended that reversible causes of heart failure are ruled out. I B\nLT-MCS implantation should be considered in patients with the following: New York Heart Association functional class IIIB–IV and\nEjection fraction ≤25% and\nAt least one of the following criteria:     ○ INTERMACS 2–4\n    ○ Inotrope dependence\n    ○ Progressive end-organ dysfunction\n    ○ Peak VO2 \u003c12 ml/kg/min\n    ○ Temporary MCS dependence IIa B\nLT-MCS implantation may be considered in patients with: New York Heart Association functional class IIIB–IV and\nEjection fraction ≤25% and\n    ○ To reverse elevated pulmonary vascular resistance or potentially reversible renal failure in potential heart transplant candidates\n    ○ To allow time for transplant contraindications to be reversed such as recent cancer, obesity and recovering drug and alcohol dependence in potential heart transplant candidates IIb B\nPatient characteristics associated with a high risk of poor outcome post-left ventricular assist device\nLT-MCS in patients with advanced age, after careful evaluation of comorbidities and frailty, should be considered. IIa C [3, 22–25]\nLT-MCS in patients with peripheral vascular disease, depending on its severity, may be considered. IIb C\nLT-MCS in patients with active systemic bacterial/fungal infection is not recommended. III B [26, 27]\nIn patients with well controlled HIV, hepatitis B or hepatitis C, LT-MCS should be considered. IIa B [26, 27]\nIn patients with diabetes with poor glycaemic control or end-organ complications, LT-MCS may still be considered. IIb B [22, 28–30]\nLT-MCS may be considered in patients with chronic dialysis. IIb C [31–34]\nLT-MCS implantation in patients with haemostatic deficiencies and coagulopathies may be considered. IIb B [35–38]\nLT-MCS implantation in patients with untreated aortic regurgitation or mechanical aortic valve is not recommended. III C [39, 40]\nLT-MCS in patients with untreated severe mitral stenosis is not recommended. III C\nLT-MCS implantation in patients with irreversible liver dysfunction, as diagnosed by liver enzyme laboratory tests and the Model of End-stage Liver Disease score, is generally not recommended. III B [41]\nIn patients with poor neurological and cognitive function, LT-MCS implantation is not recommended. III B [42, 43]\nFrail patients and patients with limited mobility may, after careful evaluation, be considered for LT-MCS implantation. IIb B [44–48]\nLT-MCS in patients who are living alone or who are suffering from depression should, after careful evaluation, be considered. IIa C [19, 49–53]\nLT-MCS implantation in patients who suffer from dementia is not recommended. III C [19, 49–53]\nLT-MCS implantation in patients with active substance abuse, not willing to cease the abuse, is not recommended. III C\nLT-MCS implantation in patients with malignancies may be considered if expected survival is \u003e1 year. IIb C [33]"}

{"project":"0_colil","denotations":[{"id":"31100109-26922275-7123","span":{"begin":1169,"end":1170},"obj":"26922275"},{"id":"31100109-16219658-7124","span":{"begin":1175,"end":1177},"obj":"16219658"},{"id":"31100109-28781010-7125","span":{"begin":1383,"end":1385},"obj":"28781010"},{"id":"31100109-21515076-7126","span":{"begin":1387,"end":1389},"obj":"21515076"},{"id":"31100109-28781010-7127","span":{"begin":1496,"end":1498},"obj":"28781010"},{"id":"31100109-21515076-7128","span":{"begin":1500,"end":1502},"obj":"21515076"},{"id":"31100109-16219658-7129","span":{"begin":1628,"end":1630},"obj":"16219658"},{"id":"31100109-16198246-7130","span":{"begin":1635,"end":1637},"obj":"16198246"},{"id":"31100109-28371075-7131","span":{"begin":1712,"end":1714},"obj":"28371075"},{"id":"31100109-19497443-7132","span":{"begin":1829,"end":1831},"obj":"19497443"},{"id":"31100109-27623098-7133","span":{"begin":1958,"end":1960},"obj":"27623098"},{"id":"31100109-19752370-7134","span":{"begin":1962,"end":1964},"obj":"19752370"},{"id":"31100109-22458997-7135","span":{"begin":2254,"end":2256},"obj":"22458997"},{"id":"31100109-25581033-7136","span":{"begin":2367,"end":2369},"obj":"25581033"},{"id":"31100109-21986099-7137","span":{"begin":2371,"end":2373},"obj":"21986099"},{"id":"31100109-22438521-7138","span":{"begin":2508,"end":2510},"obj":"22438521"},{"id":"31100109-25612862-7139","span":{"begin":2648,"end":2650},"obj":"25612862"},{"id":"31100109-24931289-7140","span":{"begin":2655,"end":2657},"obj":"24931289"},{"id":"31100109-25612862-7141","span":{"begin":2746,"end":2748},"obj":"25612862"},{"id":"31100109-24931289-7142","span":{"begin":2753,"end":2755},"obj":"24931289"},{"id":"31100109-28198133-7143","span":{"begin":2989,"end":2991},"obj":"28198133"}],"text":"Recommendation Class Level References\nIt is recommended that reversible causes of heart failure are ruled out. I B\nLT-MCS implantation should be considered in patients with the following: New York Heart Association functional class IIIB–IV and\nEjection fraction ≤25% and\nAt least one of the following criteria:     ○ INTERMACS 2–4\n    ○ Inotrope dependence\n    ○ Progressive end-organ dysfunction\n    ○ Peak VO2 \u003c12 ml/kg/min\n    ○ Temporary MCS dependence IIa B\nLT-MCS implantation may be considered in patients with: New York Heart Association functional class IIIB–IV and\nEjection fraction ≤25% and\n    ○ To reverse elevated pulmonary vascular resistance or potentially reversible renal failure in potential heart transplant candidates\n    ○ To allow time for transplant contraindications to be reversed such as recent cancer, obesity and recovering drug and alcohol dependence in potential heart transplant candidates IIb B\nPatient characteristics associated with a high risk of poor outcome post-left ventricular assist device\nLT-MCS in patients with advanced age, after careful evaluation of comorbidities and frailty, should be considered. IIa C [3, 22–25]\nLT-MCS in patients with peripheral vascular disease, depending on its severity, may be considered. IIb C\nLT-MCS in patients with active systemic bacterial/fungal infection is not recommended. III B [26, 27]\nIn patients with well controlled HIV, hepatitis B or hepatitis C, LT-MCS should be considered. IIa B [26, 27]\nIn patients with diabetes with poor glycaemic control or end-organ complications, LT-MCS may still be considered. IIb B [22, 28–30]\nLT-MCS may be considered in patients with chronic dialysis. IIb C [31–34]\nLT-MCS implantation in patients with haemostatic deficiencies and coagulopathies may be considered. IIb B [35–38]\nLT-MCS implantation in patients with untreated aortic regurgitation or mechanical aortic valve is not recommended. III C [39, 40]\nLT-MCS in patients with untreated severe mitral stenosis is not recommended. III C\nLT-MCS implantation in patients with irreversible liver dysfunction, as diagnosed by liver enzyme laboratory tests and the Model of End-stage Liver Disease score, is generally not recommended. III B [41]\nIn patients with poor neurological and cognitive function, LT-MCS implantation is not recommended. III B [42, 43]\nFrail patients and patients with limited mobility may, after careful evaluation, be considered for LT-MCS implantation. IIb B [44–48]\nLT-MCS in patients who are living alone or who are suffering from depression should, after careful evaluation, be considered. IIa C [19, 49–53]\nLT-MCS implantation in patients who suffer from dementia is not recommended. III C [19, 49–53]\nLT-MCS implantation in patients with active substance abuse, not willing to cease the abuse, is not recommended. III C\nLT-MCS implantation in patients with malignancies may be considered if expected survival is \u003e1 year. IIb C [33]"}

{"project":"2_test","denotations":[{"id":"31100109-26922275-28905183","span":{"begin":1169,"end":1170},"obj":"26922275"},{"id":"31100109-16219658-28905184","span":{"begin":1175,"end":1177},"obj":"16219658"},{"id":"31100109-28781010-28905185","span":{"begin":1383,"end":1385},"obj":"28781010"},{"id":"31100109-21515076-28905186","span":{"begin":1387,"end":1389},"obj":"21515076"},{"id":"31100109-28781010-28905187","span":{"begin":1496,"end":1498},"obj":"28781010"},{"id":"31100109-21515076-28905188","span":{"begin":1500,"end":1502},"obj":"21515076"},{"id":"31100109-16219658-28905189","span":{"begin":1628,"end":1630},"obj":"16219658"},{"id":"31100109-16198246-28905190","span":{"begin":1635,"end":1637},"obj":"16198246"},{"id":"31100109-28371075-28905191","span":{"begin":1712,"end":1714},"obj":"28371075"},{"id":"31100109-19497443-28905192","span":{"begin":1829,"end":1831},"obj":"19497443"},{"id":"31100109-27623098-28905193","span":{"begin":1958,"end":1960},"obj":"27623098"},{"id":"31100109-19752370-28905194","span":{"begin":1962,"end":1964},"obj":"19752370"},{"id":"31100109-22458997-28905195","span":{"begin":2254,"end":2256},"obj":"22458997"},{"id":"31100109-25581033-28905196","span":{"begin":2367,"end":2369},"obj":"25581033"},{"id":"31100109-21986099-28905197","span":{"begin":2371,"end":2373},"obj":"21986099"},{"id":"31100109-22438521-28905198","span":{"begin":2508,"end":2510},"obj":"22438521"},{"id":"31100109-25612862-28905199","span":{"begin":2648,"end":2650},"obj":"25612862"},{"id":"31100109-24931289-28905200","span":{"begin":2655,"end":2657},"obj":"24931289"},{"id":"31100109-25612862-28905201","span":{"begin":2746,"end":2748},"obj":"25612862"},{"id":"31100109-24931289-28905202","span":{"begin":2753,"end":2755},"obj":"24931289"},{"id":"31100109-28198133-28905203","span":{"begin":2989,"end":2991},"obj":"28198133"}],"text":"Recommendation Class Level References\nIt is recommended that reversible causes of heart failure are ruled out. I B\nLT-MCS implantation should be considered in patients with the following: New York Heart Association functional class IIIB–IV and\nEjection fraction ≤25% and\nAt least one of the following criteria:     ○ INTERMACS 2–4\n    ○ Inotrope dependence\n    ○ Progressive end-organ dysfunction\n    ○ Peak VO2 \u003c12 ml/kg/min\n    ○ Temporary MCS dependence IIa B\nLT-MCS implantation may be considered in patients with: New York Heart Association functional class IIIB–IV and\nEjection fraction ≤25% and\n    ○ To reverse elevated pulmonary vascular resistance or potentially reversible renal failure in potential heart transplant candidates\n    ○ To allow time for transplant contraindications to be reversed such as recent cancer, obesity and recovering drug and alcohol dependence in potential heart transplant candidates IIb B\nPatient characteristics associated with a high risk of poor outcome post-left ventricular assist device\nLT-MCS in patients with advanced age, after careful evaluation of comorbidities and frailty, should be considered. IIa C [3, 22–25]\nLT-MCS in patients with peripheral vascular disease, depending on its severity, may be considered. IIb C\nLT-MCS in patients with active systemic bacterial/fungal infection is not recommended. III B [26, 27]\nIn patients with well controlled HIV, hepatitis B or hepatitis C, LT-MCS should be considered. IIa B [26, 27]\nIn patients with diabetes with poor glycaemic control or end-organ complications, LT-MCS may still be considered. IIb B [22, 28–30]\nLT-MCS may be considered in patients with chronic dialysis. IIb C [31–34]\nLT-MCS implantation in patients with haemostatic deficiencies and coagulopathies may be considered. IIb B [35–38]\nLT-MCS implantation in patients with untreated aortic regurgitation or mechanical aortic valve is not recommended. III C [39, 40]\nLT-MCS in patients with untreated severe mitral stenosis is not recommended. III C\nLT-MCS implantation in patients with irreversible liver dysfunction, as diagnosed by liver enzyme laboratory tests and the Model of End-stage Liver Disease score, is generally not recommended. III B [41]\nIn patients with poor neurological and cognitive function, LT-MCS implantation is not recommended. III B [42, 43]\nFrail patients and patients with limited mobility may, after careful evaluation, be considered for LT-MCS implantation. IIb B [44–48]\nLT-MCS in patients who are living alone or who are suffering from depression should, after careful evaluation, be considered. IIa C [19, 49–53]\nLT-MCS implantation in patients who suffer from dementia is not recommended. III C [19, 49–53]\nLT-MCS implantation in patients with active substance abuse, not willing to cease the abuse, is not recommended. III C\nLT-MCS implantation in patients with malignancies may be considered if expected survival is \u003e1 year. IIb C [33]"}